rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RLMD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Relmada appoints Jørn Jakobsen as chief development officer
      Nov 16Investing.comRLMD
      What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceRLMD
      Earnings call transcript: Relmada Therapeutics narrows loss as cash runway extends in Q3 2026
      Nov 12Investing.comRLMD
      Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call - Relmada Therapeutics (NASDAQ:RLMD)

      Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time

      Oct 12BenzingaRLMD
      Alpha Buying: 4 Biotech Stocks Insiders Are Betting On - Xenon Pharmaceuticals (NASDAQ:XENE), MAIA Biotec

      I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.

      Oct 8BenzingaRLMDMAIA
      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Sep 29BenzingaEVGNRLMD
      Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement
      Sep 14Seeking AlphaRLMD
      Relmada CEO Sergio Traversa buys 200,000 shares for $828,000
      Sep 11Investing.comRLMD
      Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares
      Sep 11Investing.comRLMD
      Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

      Relmada Therapeutics (RLMD) shares were up nearly 11% in afternoon trading on Friday after the compa

      Sep 11Yahoo FinanceRLMD
      Relmada Therapeutics Announces Urology Chief Medical Officer Exit

      Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailRLMD
      Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

      CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o

      Sep 1Yahoo FinanceRLMD
      After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

      Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

      Aug 31Yahoo FinanceRLMD
      Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

      Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

      Aug 25Yahoo FinanceRLMD

      This is the newest page. Registered accounts read further back.